Miracell Selected as One of the “1000 National Innovative Companies in the Health and Diagnostics Sector”
Stem cell specialist Miracell has been selected as one of the government’s “1000 Innovative Companies.”
According to the company on the 1st, Miracell was selected for the third round of the “1000 Innovative Companies,” announced by the Financial Services Commission, based on evaluations by nine government ministries, including the Ministry of Trade, Industry and Energy and the Ministry of Health and Welfare. This time, 321 companies were selected.
Miracell was selected as one of the “Health and Diagnostic Innovation Companies” in the health technology, medical device, and innovative pharmaceutical categories, according to the Ministry of Health and Welfare’s selection criteria.
Launched in 2009 as a stem cell specialist company with the introduction of Harvard University’s cell extraction technology,
the company successfully developed a “minimally manipulated stem cell isolation and amplification source technology” in 2017. The Ministry of SMEs and Startups selected this technology as a technology development project for commercialization by small and medium-sized enterprises.
In 2018, Miracell successfully developed and domestically produced the Smart Mcell 2 kit, a replacement for the Smart Prep kit developed by the Harvard Medical School’s Immunology Research Institute and exported worldwide.
CEO Shin Hyun-soon stated, “Being selected as a national innovative company is very significant. This opens up a new avenue for scientifically treating rare and intractable diseases, including Parkinson’s disease and intractable chronic renal failure, using stem cells.”
Meanwhile, Miracell, which began its medical business in 1986, has been dedicated to research and development as a stem cell specialist since 2007.
In particular, its biological drug manufacturing technology has been certified by the Ministry of Health and Welfare as a new medical technology that helps treat conditions such as acute myocardial infarction, critical limb ischemia, and cartilage defects.
Reporter Kim Si-young kimsy@asiatoday.co.kr